Enhancement of chlorpromazine efficacy in breast cancer treatment by 266 nm laser irradiation

Sci Rep. 2024 Dec 5;14(1):30329. doi: 10.1038/s41598-024-82088-1.

Abstract

Breast cancer remains a global health challenge, prompting interest in the anticancer properties of other drugs, including chlorpromazine (CPZ). This study presents a novel approach in breast cancer treatment using laser irradiated CPZ. CPZ dissolved in distilled water, was exposed to 266 nm laser irradiation for varying durations, characterized by UV-Vis and FTIR spectroscopy, followed by drug-likeness and ADME-Tox predictions. In vitro assays evaluated the cytotoxicity and cellular effects on MCF-7 breast cancer cells, and compared with MCF-12 A healthy cell line. Laser irradiation altered CPZ molecular structure resulting in photoproducts with favourable drug-like properties and ADME-Tox profiles. In vitro evaluations demonstrate dose and irradiation time-dependent cytotoxicity against breast cancer cells, and reduced toxicity on healthy cell line. Significant alterations in F-actin organization, and excessive ROS generation were also proved, suggesting the potential of laser-modified CPZ for breast cancer therapy. This study introduces a novel approach to breast cancer treatment through laser irradiated CPZ, highlighting promising advancements in therapy and emphasizing the role of laser-generated compounds.

Keywords: ADME-Tox; Antipsychotic drugs; Breast cancer; Chlorpromazine; Drug repositioning; Laser-irradiated drugs.

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / radiotherapy
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Chlorpromazine* / pharmacology
  • Female
  • Humans
  • Lasers
  • MCF-7 Cells
  • Reactive Oxygen Species / metabolism

Substances

  • Chlorpromazine
  • Reactive Oxygen Species
  • Antineoplastic Agents